New data from a trial of lasofoxifene, a selective oestrogen-receptor modulator (SERM) show five years of treatment in postmenopausal osteoporotic women does not increase the risk of endometrial cancer or hyperplasia.
The study of >8500 women found lasofoxifene resulted in a small increase in endometrial thickness versus placebo, the authors said.
The new study follows the release of data last year suggesting lasofoxifene reduced the risk of breast cancer in women in the randomised, placebo-controlled PEARL (Postmenopausal Evaluation and Risk-Reduction With Lasofoxifene) trial.
Content updated 31 January 2011
